Trial Profile

A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Ramucirumab (Primary) ; SYSA 1801 (Primary)
Indications Adenocarcinoma; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors Elevation Oncology

20 Mar 2025 According to an Elevation Oncology media release, the company discontinue further development of EO-3021 based on data from the dose escalation and expansion stages of Elevation Oncology's Phase 1 trial.
20 Mar 2025 Status changed from recruiting to discontinued.
13 Jan 2025 According to an Elevation Oncology media release, the company has started dosing in combination portion of the trial and expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com